New York, USA – August 17, 2021 – DDA platform, the division of Creative Bioarray, focuses on developing high quality products and services as drug discovery accelerator. With the most highly experienced and specialized staff in pharmacology, DDA platform provides integrated drug discovery services to pharma, biotechnology companies, and academic institutions around the world. Recently, it announced the release of its in vitro ADME service for drug discovery organizations.
The in vitro ADME tests provided by the DDA platform include multiple forms to adapt to different stages of the drug discovery pipeline, thereby providing a flexible method for ADME services. Although Creative Bioarray has standard procedures for each test, the experienced research team can also help design customized best strategies and programs to meet any drug discovery needs.
Creative Bioarray has developed a variety of experimental methods for measuring solubility, including kinetic, semi-equilibrium and equilibrium methods. Generally, kinetic or semi-equilibrium methods are used for early drug discovery as high-throughput analysis to analyze a large number of compounds, while medium-throughput and/or low-throughput equilibrium methods are used in the later stages of drug discovery and development.
Creative Bioarray provides a wide range of complementary in vitro models to evaluate drug permeability and predict drug absorption and distribution. With decades of operating experience, Creative Bioarray is able to provide a variety of analysis services based on the penetration rate model. All absorption and permeability measurements can be used in standard human and animal model systems, and can be ordered individually, in combination, or as an option for key services in the candidate evaluation package.
In addition, Creative Bioarray provides a wide range of biological systems to determine in vitro metabolic stability, including primary hepatocytes from various preclinical species, tissue homogenates and tissue parts (such as microsomes, mitochondrial preparations, S9 parts and Intestinal juice). The service is incubated with appropriate cofactors in a suitable test system (S9, microsomes, hepatocytes, recombinant CYP enzymes), and evaluated at multiple time points, in triplicate, and additional critical samples repetition.
“Our well-trained and experienced scientific team provides clients with extensive and in-depth expertise in appropriate research design, research execution and data interpretation.” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “We also provide extensive drug metabolism and pharmacokinetic capabilities for new chemical entities and compounds under development. Our team is always dedicated to supporting you in a leading position in terms of competitive timelines and effective advice.”
About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.
Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-386-8241
Country: United States
Website: https://dda.creative-bioarray.com
